Document:

<PAGE>

                                                                   EXHIBIT 10.19

                             Subject to Approval by CancerVax Board of Directors
                                                                    CONFIDENTIAL

                              EMPLOYMENT AGREEMENT

         This Employment Agreement (the "Agreement") is effective as of the
Service Commencement Date (as defined in Section 1, below), between CancerVax
Corporation, a Delaware corporation (the "Company"), and MARTIN A. MATTINGLY, an
individual ("Executive"), with reference to the following:

                                    RECITALS

         WHEREAS, the Company has agreed to employ Executive and Executive has
agreed to accept such employment on the terms and conditions set forth herein.

         NOW, THEREFORE, in consideration of the various covenants and
agreements hereinafter set forth, the parties hereto agree as follows:

         1. Term of Employment. The Company hereby employs Executive and
Executive accepts such employment commencing on May 15, 2003, or such other date
as Executive and Company may mutually agree upon in writing (the "Service
Commencement Date") and terminating on the fourth anniversary hereof, unless
sooner terminated as hereinafter provided.

         2. Services to be Rendered.

                  2.1.     Duties. Executive shall serve as Executive Vice
President, Marketing and Business Development, of the Company, or in such other
capacity with the Company, any company into which the Company may be merged or
any present or future subsidiary of either of them, as the Board of Directors of
the Company (the "Board") or the Chief Executive Officer of the Company ("CEO")
may assign to Executive in connection with the business of the Company (the
"Company Business"). In the performance of such duties, Executive shall report
directly to the CEO and shall be subject to the direction of the CEO and to such
limits upon Executive's authority as the CEO may from time to time impose.
Executive hereby consents to serve as an officer and/or director of the Company
or any subsidiary or affiliate thereof without any additional salary or
compensation, if so requested by the Board. Executive shall be employed by the
Company on a full time basis. Executive's place of work shall be at the
Corporation's headquarters in Carlsbad, CA or such other location within San
Diego County, as may be designated by the CEO from time to time. However,
Executive shall also render services at such other place or places within or
without the United States as the CEO may direct from time to time. Executive
shall be subject to the policies and procedures generally applicable to senior
executives of the Company to the extent the same are not inconsistent with any
term of this Agreement.

                  2.2.     Exclusive Services. Executive shall at all times
faithfully, industriously and to the best of his ability, experience and talent
perform to the satisfaction of the Board and the CEO all of the duties that may
be assigned to Executive hereunder and, except as set forth in Section 2.1,
shall devote all of his productive time and efforts to the

<PAGE>

                                   Subject to Approval by the Board of Directors

performance of such duties. Executive may devote time to personal and family
investments to the extent that the time so spent does not conflict with the
Company Business. The existence of such a conflict shall be determined in good
faith by the Board.

         3. Compensation and Benefits. The Company shall pay the following
compensation and benefits to Executive during the term hereof, and Executive
shall accept the same as payment in full for all services rendered by Executive
to or for the benefit of the Company:

                  3.1.     Salary. The Company shall pay to Executive an
annualized salary ("Base Salary") of Two Hundred Sixty Thousand Dollars
($260,000.00). Thereafter, annual salary reviews will occur every February 1.
The Base Salary shall accrue in equal monthly installments in arrears and shall
be payable in accordance with the payroll practices of the Company in effect
from time to time. The Executive's first ninety (90) days of employment with
CancerVax Corporation are considered an Introductory Period. Completion of the
Introductory Period does not guarantee continued employment for any specified
period of time, nor does it require that a dismissal be based on cause.

                  3.2.     Bonus. Executive shall be eligible to participate in
the CancerVax Corporation Management Incentive Compensation Plan, as approved by
the Company's Board of Directors from time to time, or in such other bonus plan
as the Board of Directors may approve for the Senior Executives of the
Corporation.

                  3.3.     Fringe Benefits. Executive shall be entitled to
participate in benefits under the Company's benefit plans and arrangements,
including, without limitation, any employee benefit plan or arrangement made
available in the future by the Company to its senior executives, subject to and
on a basis consistent with the terms, conditions and overall administration of
such plans and arrangements. The Company shall have the right to amend or delete
any such benefit plan or arrangement made available by the Company to its senior
executives and not otherwise specifically provided for herein.

                  3.4.     Expenses. The Company shall reimburse Executive for
reasonable out-of-pocket expenses incurred in connection with the Company
Business and the performance of his duties hereunder, subject to (i) such
policies as the Company may from time to time establish, (ii) Executive
furnishing the Company with evidence in the form of receipts satisfactory to the
Company substantiating the claimed expenditures, (iii) Executive receiving
advance approval from the CEO in the case of expenses for travel outside of
North America and (iv) Executive receiving advance approval from the CEO in case
of expenses (or a series of related expenses) in excess of $5,000. It is agreed
that the Company shall reimburse Executive for reasonable legal fees he actually
incurs in connection with the review of these employment arrangements in an
amount not to exceed Two Thousand Dollars ($2,000.00). Executive shall provide
evidence reasonably satisfactory to the Company of all such legal fees.

                  3.5.     Vacation. Executive shall be entitled to the number
of paid vacation days, but not less than twenty (20) days, in each calendar year
determined by the Company

                                       -2-

<PAGE>

                                   Subject to Approval by the Board of Directors

from time to time for its senior executive officers. Executive shall also be
entitled to all paid holidays given to the Company's senior executive officers.

                  3.6.     Stock Options. Subject to the approval of the
Company's Board of Directors or its Compensation Committee, Executive shall be
granted an option to purchase Four Hundred Thousand (400,000) shares of the
Company's common stock. The exercise price per share shall be equal to the fair
market value per share on the date the option is granted or on Executive's first
day of service, whichever is later (the "Grant Date"). The option shall be
subject to the terms and conditions applicable to options granted under the
Company's 2000 Stock Incentive Plan (the "Plan"), as amended, as described in
such Plan and the applicable stock option agreement, the form of which is
attached to this Agreement as Exhibit A. Executive shall vest in Twenty-five
Thousand shares (25,000) upon the Grant Date, and the balance of the shares
(Three Hundred Seventy-five Thousand (375,000) shares) shall vest in monthly
installments over the forty-eight (48) months of service following such date, as
described in the applicable stock option agreement. In addition to any
accelerated vesting provisions under the Plan, (a) upon a Corporate Transaction
(as defined in the Plan), 50% of the then unvested portion of the Option shall
accelerate, vest and become exercisable and (b) upon any termination by the
Company of Executive's employment under this Agreement for Company Convenience
as defined in Section 7.3, or by the Executive following a Corporate Transaction
for Good Reason (as such terms are defined in the Plan), the number of stock
options shall vest upon the effective date of such termination which would have
vested if Executive had remained employed during the Severance Period described
in Section 7.4 (without regard to any other vesting acceleration triggers). The
exercise price of the Option shall be equal to the fair market value of the
Company's common stock as determined by the Board at the time of grant.

                  3.7.     Withholding and other Deductions. All compensation
payable to Executive hereunder shall be subject to such deductions as the
Company is from time to time required to make pursuant to law, governmental
regulation or order.

         4. Representations and Warranties.

         Executive represents and warrants to the Company that (a) Executive is
under no contractual or other restriction or obligation which is inconsistent
with the execution of this Agreement, the performance of his duties hereunder,
or the other rights of the Company hereunder and (b) Executive is under no
physical or mental disability that would hinder the performance of his duties
under this Agreement.

         The Company represents and warrants that, following the approval of
this Agreement by its Board: (a) it is fully authorized to enter into this
Agreement and to perform its obligations under it; (b) the execution and
delivery of this Agreement by it does not violate any applicable law,
regulation, order, judgment or decree or any agreement, plan or corporate
governance document to which it is a party or by which it is bound; and (c) upon
the execution and delivery of this Agreement by both parties hereto, this
Agreement shall be a valid and binding obligation of the Company, enforceable
against it in accordance with its

                                       -3-

<PAGE>

                                   Subject to Approval by the Board of Directors

terms, except to the extent that enforceability may be limited by applicable
bankruptcy, insolvency or similar laws affecting the enforcement of creditors'
rights generally.

         5. Certain Covenants.

                  5.1.     Non-competition. Except as may otherwise be approved
by the Board, during the term of this Agreement, Executive shall not have any
ownership interest (of record or beneficial) in, or have any interest as an
employee, salesman, consultant, officer or director in, or otherwise aid or
assist in any manner, any firm, corporation, partnership, proprietorship or
other business that engages in any county, city or part thereof in the United
States and/or any foreign country in a business which competes directly or
indirectly (as determined by the Board) with the Company's business in such
county, city or part thereof, so long as the Company, or any successor in
interest of the Company to the business and goodwill of the Company, remains
engaged in such business in such county, city or part thereof or continues to
solicit customers or potential customers therein; provided, however, that
Executive may own, directly or indirectly, solely as an investment, securities
of any entity which are traded on any national securities exchange if Executive
(a) is not a controlling person of, or a member of a group which controls, such
entity; or (b) does not, directly or indirectly, own one percent (1%) or more of
any class of securities of any such entity.

                  5.2.     Trade Secrets. Executive acknowledges that the nature
of Executive's engagement by the Company is such that Executive will have access
to Confidential Information (defined below) which has great value to the Company
and that except for Executive's engagement by the Company, Executive would not
otherwise have access to the Confidential Information. During the term of this
Agreement and at all times thereafter, Executive shall keep all of the
Confidential Information in confidence and shall not disclose any of the same to
any other person, except: (a) as necessary in the performance of his services
under this Agreement, provided that any such disclosures shall be in accordance
with the Company's policies and procedures; (b) to the Company's personnel
entitled thereto; and (c) to other persons designated in writing by the Company.
Executive shall not cause, suffer or permit the Confidential Information to be
used for the gain or benefit of any party outside of the Company or for
Executive's personal gain or benefit outside the scope of Executive's engagement
by the Company. Executive shall sign the Company's standard form of invention
assignment and confidentiality agreement upon the Company's request. Anything
herein to the contrary notwithstanding, Executive may disclose Confidential
Information if required to do so by legal process or in a judicial or
administrative proceeding, provided that Executive shall give reasonable advance
notice to the Company of such disclosure requirement so that the Company may
seek a protective order and or other appropriate remedy or waive compliance with
the confidentiality provisions of this Agreement, and will cooperate fully with
the Company's reasonable efforts to secure confidential treatment of such
Confidential Information required to be disclosed.

                  5.3.     Solicitation of Employees. Executive shall not during
the term hereof and for the one year period following any expiration or
termination hereof (the "Restricted

                                       -4-

<PAGE>

                                   Subject to Approval by the Board of Directors

Period"), directly or indirectly, hire, solicit or encourage to leave the
employment of the Company or any of its affiliates, any employee of the Company
or any of its affiliates or hire any such employee who has left the employment
of the Company or any of its affiliates within one year of the termination of
such employee's employment with the Company or any of its affiliates.

                  5.4.     Solicitation of Consultants. Executive shall not
during the Restricted Period, directly or indirectly, hire, solicit or encourage
to cease work with the Company or any of its affiliates any consultant then
under contract with the Company or any of its affiliates within one year of the
termination of such consultant's engagement by the Company or any of its
affiliates.

                  5.5.     Rights and Remedies Upon Breach. If Executive
breaches or threatens to commit a breach of any of the provisions of this
Section 5 (the "Restrictive Covenants"), the Company shall have the following
rights and remedies, each of which rights and remedies shall be independent of
the other and severally enforceable, and all of which rights and remedies shall
be in addition to, and not in lieu of, any other rights and remedies available
to the Company under law or in equity:

                           (i)      Specific Performance. The right and remedy
to have the Restrictive Covenants specifically enforced by any court having
equity jurisdiction, all without the need to post a bond or any other security
or to prove any amount of actual damage or that money damages would not provide
an adequate remedy, it being acknowledged and agreed that any such breach or
threatened breach will cause irreparable injury to the Company and that money
damages will not provide adequate remedy to the Company; and

                           (ii)     Accounting and Indemnification. The right
and remedy to require Executive (i) to account for and pay over to the Company
all compensation, profits, monies, accruals, increments or other benefits
derived or received by Executive or any associated party deriving such benefits
as a result of any such breach of the Restrictive Covenants; and (ii) to
indemnify the Company against any other losses, damages (including special and
consequential damages), costs and expenses, including actual attorneys' fees and
court costs, which may be incurred by them and which result from or arise out of
any such breach or threatened breach of the Restrictive Covenants.

                  5.6.     Severability of Covenants/Blue Pencilling. If any
court determines that any of the Restrictive Covenants, or any part thereof, is
invalid or unenforceable, the remainder of the Restrictive Covenants shall not
thereby be affected and shall be given full effect, without regard to the
invalid portions. If any court determines that any of the Restrictive Covenants,
or any part thereof, are unenforceable because of the duration of such provision
or the area covered thereby, such court shall have the power to reduce the
duration or area of such provision and, in its reduced form, such provision
shall then be enforceable and shall be enforced. Executive hereby waives any and
all right to attack the validity of the

                                       -5-

<PAGE>

                                   Subject to Approval by the Board of Directors

Restrictive Covenants on the grounds of the breadth of their geographic scope or
the length of their term.

                  5.7.     Enforceability in Jurisdictions. The Company and
Executive intend to and do hereby confer jurisdiction to enforce the Restrictive
Covenants upon the courts of any jurisdiction within the geographical scope of
such covenants. If the courts of any one or more of such jurisdictions hold the
Restrictive Covenants wholly unenforceable by reason of the breadth of such
scope or otherwise, it is the intention of the Company and Executive that such
determination not bar or in any way affect the right of the Company to the
relief provided above in the courts of any other jurisdiction within the
geographical scope of such covenants, as to breaches of such covenants in such
other respective jurisdictions, such covenants as they relate to each
jurisdiction being, for this purpose, severable into diverse and independent
covenants.

                  5.8.     Definitions.

                           (i)      The term "Company", as used in Sections 5.1
- 5.7, means not only CancerVax Corporation, but also any company, partnership
or entity which, directly or indirectly, controls, is controlled by or is under
common control with CancerVax Corporation.

                           (ii)     The term "Confidential Information", as used
herein, means all information or material not generally known by non-Company
personnel which (i) gives the Company some competitive business advantage or the
opportunity of obtaining such advantage or the disclosure of which could be
detrimental to the interests of the Company; (ii) which is owned by the Company
or in which the Company has an interest and (iii) which is either (A) marked
"Confidential Information," "Proprietary Information" or other similar marking,
(B) known by Executive to be considered confidential and proprietary by the
Company or (C) from all the relevant circumstances should reasonably be assumed
by Executive to be confidential and proprietary to the Company. Confidential
Information includes, but is not limited to, the following types of information
and other information of a similar nature (whether or not reduced to writing):
trade secrets, inventions, drawings, file data, documentation, diagrams,
specifications, know how, processes, formulas, models, flow charts, software in
various stages of development, source codes, object codes, research and
development procedures, research or development and test results, marketing
techniques and materials, marketing and development plans, price lists, pricing
policies, business plans, information relating to customers and/or suppliers'
identities, characteristics and agreements, financial information and
projections, and Executive files. Confidential Information also includes any
information described above which the Company obtains from another party and
which the Company treats as proprietary or designates as Confidential
Information, whether or not owned or developed by the Company. NOTWITHSTANDING
THE ABOVE, HOWEVER, NO INFORMATION CONSTITUTES CONFIDENTIAL INFORMATION IF IT IS
GENERIC INFORMATION OR GENERAL KNOWLEDGE WHICH COVENANTOR WOULD HAVE LEARNED IN
THE COURSE OF SIMILAR

                                       -6-

<PAGE>

                                   Subject to Approval by the Board of Directors

EMPLOYMENT ELSEWHERE IN THE TRADE OR IF IT IS OTHERWISE PUBLICLY KNOWN AND IN
THE PUBLIC DOMAIN.

         6. Insurance. The Company shall have the right to take out life,
health, accident, "key-man" or other insurance covering Executive, in the name
of the Company and at the Company's expense in any amount deemed appropriate by
the Company. Executive shall assist the Company in obtaining such insurance,
including, without limitation, submitting to any required examinations and
providing information and data required by insurance companies.

         7. Termination.

                  7.1.     Death or Total Disability of Executive. If Executive
dies or becomes totally disabled during the term of this Agreement, Executive's
employment hereunder shall automatically terminate. For these purposes,
Executive shall be deemed totally disabled if Executive shall become physically
or mentally incapacitated or disabled or otherwise unable fully to discharge
Executive's duties hereunder for a period of ninety (90) consecutive calendar
days or for 120 calendar days in any 180 calendar-day period.

                  7.2.     Termination for Good Cause. Executive's employment
hereunder may be terminated by the Company for "good cause." The term "good
cause" is defined as any one or more of the following occurrences:

                           (i)      Executive's breach of any of the covenants
contained in Section 5 of this Agreement;

                           (ii)     Executive's conviction by, or entry of a
plea of guilty or nolo contendere in, a court of competent and final
jurisdiction for any crime involving moral turpitude or punishable by
imprisonment in the jurisdiction involved;

                           (iii)    Executive's commission of an act of fraud,
whether prior to or subsequent to the date hereof upon the Company;

                           (iv)     Executive's continuing repeated willful
failure or refusal to perform Executive's duties as required by this Agreement
(including, without limitation, Executive's inability to perform Executive's
duties hereunder as a result of chronic alcoholism or drug addiction and/or as a
result of any failure to comply with any laws, rules or regulations of any
governmental entity with respect to Executive's employment by the Company);

                           (v)      Executive's gross negligence,
insubordination or material violation of any duty of loyalty to the Company or
any other material misconduct on the part of Executive;

                           (vi)     Executive's commission of any act which is
detrimental to the Company's business or goodwill; or

                                       -7-

<PAGE>

                                   Subject to Approval by the Board of Directors

                           (vii)    Executive's breach of any other provision of
this Agreement, provided that termination of Executive's employment pursuant to
this subsection (vii) shall not constitute valid termination for good cause
unless Executive shall have first received written notice from the Board stating
with specificity the nature of such breach and affording Executive at least
fifteen (15) days to correct the breach alleged.

                  7.3.     Company Convenience or Good Reason. The Company may
terminate Executive's employment at any time and without cause and for any
reason or for no reason at the Company's sole discretion ("Company
Convenience"), effective five (5) days after notice to Executive. Executive may
terminate his employment at any time with or without Good Reason (as such term
is defined in the Plan).

                  7.4.     Severance Compensation. Upon the occurrence of any of
the events referred to in Sections 7.1 and 7.2 above, Executive (or Executive's
heirs or representatives) shall be entitled to receive only such portion (if
any) of the Base Salary as may theretofore have accrued but be unpaid on the
date on which the termination shall take effect. Upon the termination of
Executive's employment for Company Convenience, or upon Executive's termination
of his employment with the Company following a Corporate Transaction for Good
Reason (as such terms are defined in the Plan), the Company shall continue to
pay to Executive, as severance pay, Executive's Base Salary as provided in
Section 3.1 above, for a period of 12 months after the effective date of such
termination and a bonus equal to the average of the prior annual bonuses paid in
accordance with the CancerVax Corporation Management Incentive Compensation Plan
(disregarding any year when no bonus was paid), if any.

                  7.5.     Return of the Company's Property. If this Agreement
is terminated for any of the foregoing reasons, the Company shall have the
right, at its option, to require Executive to vacate his offices prior to the
effective date of termination and to cease all activities on the Company's
behalf. Upon the termination of his employment in any manner, Executive shall
immediately surrender to the Company all lists, books and records of, or in
connection with, the Company's business, and all other property belonging to the
Company, it being distinctly understood that all such lists, books and records,
and other documents, are the property of the Company.

                  7.6.     Waiver of the Company's Liability. Executive
recognizes that this Agreement is subject to termination with or without cause
for any reason and therefore Executive agrees that Executive shall hold the
Company harmless from and against any and all liabilities, losses, damages,
costs and expenses, including but not limited to, court costs and reasonable
attorneys' fees, which Executive may incur as a result of the termination of
this Agreement. Executive further agrees that Executive shall bring no claim or
cause of action against the Company for damages or injunctive relieve based on a
wrongful termination of employment. Executive agrees that the sole liability of
the Company to Executive upon termination of this Agreement shall be that
determined by Section 7.4 herein. In the event this covenant is more restrictive
than permitted by laws of the jurisdiction in

                                       -8-

<PAGE>

                                   Subject to Approval by the Board of Directors

which the Company seeks enforcement thereof, this covenant shall be limited to
the extent permitted by law.

         8. Arbitration. Except as provided in Section 5.7, any claim or
controversy arising out of or relating to this Agreement shall be settled by
arbitration in San Diego, California, in accordance with the Commercial
Arbitration Rules of the American Arbitration Association, and judgment on the
award rendered by the arbitrator may be entered in any court having
jurisdiction. Each party shall select one arbitrator and the two arbitrators so
chosen will select a third arbitrator who shall act as the sole arbitrator of
any dispute. Each party shall pay the fees of its own attorneys, the expenses of
its witnesses and all other expenses connected with presenting its case. Other
costs of the arbitration, including the cost of any record or transcripts of the
arbitration, administrative fees, the fee of the sole arbitrator, and all other
fees and costs, shall be borne by the Company.

         9. General Relationship. Executive shall be considered an employee of
the Company within the meaning of all federal, state and local laws and
regulations including, but not limited to, laws and regulations governing
unemployment insurance, workers' compensation, industrial accident, labor and
taxes.

         10. Miscellaneous.

                  10.1.    Modification; Prior Claims. This Agreement sets forth
the entire understanding of the parties with respect to the subject matter
hereof, and supersedes all existing agreements between them concerning such
subject matter including, without limitation, the offer letter to Executive from
the Company dated as of February 28, 2003, and may be modified only by a written
instrument duly executed by each party. Notwithstanding the foregoing, the
Confidential Disclosure Agreement executed between the parties as of April ___,
2003 (the "CDA"), shall remain in full force and effect and shall govern with
respect to all disclosures of Confidential Information (as such term is defined
in the CDA) from the Company to Executive prior to the Service Commencement
Date.

                  10.2.    Assignment. The rights of the Company under this
Agreement may, without the consent of Executive, be assigned by the Company, in
its sole and unfettered discretion, to any person, firm, corporation or other
business entity which at any time, whether by purchase, merger or otherwise,
directly or indirectly, acquires all or substantially all of the assets or
business of the Company.

                  10.3.    Survival. The covenants, agreements, representations
and warranties contained in or made in Sections 3.7, 5.2, 5.3, 5.4, 5.5, 5.6,
5.7, 5.8, 7.4, 7.5, 7.6, 8 and 10 of this Agreement shall survive any
termination of Executive's employment.

                  10.4.    Third-Party Beneficiaries. This Agreement does not
create, and shall not be construed as creating, any rights enforceable by any
person not a party to this Agreement.

                                       -9-

<PAGE>

                                   Subject to Approval by the Board of Directors

                  10.5.    Waiver. The failure of either party hereto at any
time to enforce performance by the other party of any provision of this
Agreement shall in no way affect such party's rights thereafter to enforce the
same, nor shall the waiver by either party of any breach of any provision hereof
be deemed to be a waiver by such party of any other breach of the same or any
other provision hereof.

                  10.6.    Hiring At Will. Any continuance of Executive's
employment by the Company after the term hereof shall be deemed a hiring at will
(unless such continuance is the subject of a new written agreement) and shall be
subject to termination with or without cause by either party upon delivery of
notice thereof.

                  10.7.    Section Headings. The headings of the several
sections in this Agreement are inserted solely for the convenience of the
parties and are not a part of and are not intended to govern, limit or aid in
the construction of any term or provision hereof.

                  10.8.    Notices. All notices, requests and other
communications hereunder shall be in writing and shall be delivered by courier
or other means of personal service (including by means of a nationally
recognized courier service or professional messenger service), or sent by telex
or telecopy or mailed first class, postage prepaid, by certified mail, return
receipt requested, in all cases, addressed to:

                           Company:
                                    CancerVax Corporation
                                    2110 Rutherford Road
                                    Carlsbad, CA 92008
                                    Attention: Chief Executive Officer
                           Executive:
                                    Martin A. Mattingly
                                    13910 Rancho Solana Trail
                                    San Diego, CA 92130

All notices, requests and other communications shall be deemed given on the date
of actual receipt or delivery as evidenced by written receipt, acknowledgement
or other evidence of actual receipt or delivery to the address. In case of
service by telecopy, a copy of such notice shall be personally delivered or sent
by registered or certified mail, in the manner set forth above, within three
business days thereafter. Any party hereto may from time to time by notice in
writing served as set forth above designate a different address or a different
or additional person to which all such notices or communications thereafter are
to be given.

                  10.9.    Severability. All Sections, clauses and covenants
contained in this Agreement are severable, and in the event any of them shall be
held to be invalid by any court, this Agreement shall be interpreted as if such
invalid Sections, clauses or covenants were not contained herein.

                  10.10.   Governing Law and Venue. This Agreement is to be
governed by and construed in accordance with the laws of the State of California
applicable to contracts made

                                      -10-

<PAGE>

                                   Subject to Approval by the Board of Directors

and to be performed wholly within such State, and without regard to the
conflicts of laws principles thereof. Except as provided in Sections 5.7 and 8,
any suit brought hereon shall be brought in the state or federal courts sitting
in Los Angeles, California, the parties hereto hereby waiving any claim or
defense that such forum is not convenient or proper. Each party hereby agrees
that any such court shall have in personam jurisdiction over it and consents to
service of process in any manner authorized by California law.

                  10.11.   Non-transferability of Interest. None of the rights
of Executive to receive any form of compensation payable pursuant to this
Agreement shall be assignable or transferable except through a testamentary
disposition or by the laws of descent and distribution upon the death of
Executive. Any attempted assignment, transfer, conveyance, or other disposition
(other than as aforesaid) of any interest in the rights of Executive to receive
any form of compensation to be made by the Company pursuant to this Agreement
shall be void.

                  10.12.   Attorneys' Fees. Subject to the provisions of Section
8 hereof with respect to arbitration, if any legal action, arbitration or other
proceeding is brought for the enforcement of this Agreement, or because of any
alleged dispute, breach, default or misrepresentation in connection with this
Agreement, the successful or prevailing party shall be entitled to recover
reasonable attorneys' fees and other costs it incurred in that action or
proceeding, in addition to any other relief to which it may be entitled.

                  10.13.   Gender. Where the context so requires, the use of the
masculine gender shall include the feminine and/or neuter genders and the
singular shall include the plural, and vice versa, and the word "person" shall
include any corporation, firm, partnership or other form of association.

                  10.14.   Counterparts. This Agreement may be executed in one
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same Agreement.

                  10.15.   Construction. The language in all parts of this
Agreement shall in all cases be construed simply, according to its fair meaning,
and not strictly for or against any of the parties hereto. Without limitation,
there shall be no presumption against any party on the ground that such party
was responsible for drafting this Agreement or any part thereof.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                      -11-

<PAGE>

                                   Subject to Approval by the Board of Directors

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date hereinabove set forth.

                                                   THE COMPANY
                                                   CancerVax Corporation,
                                                   a Delaware corporation

                                                   By: /s/ David F. Hale
                                                       -------------------------
                                                       David F. Hale
                                                       Its: President and CEO

                                                   EXECUTIVE

                                                       /s/ Martin A. Mattingly
                                                       -------------------------
                                                       Martin A. Mattingly

                                      -12-

<PAGE>

                                   Subject to Approval by the Board of Directors

                                    EXHIBIT A

                         FORM OF STOCK OPTION AGREEMENT

                                      -13-

<PAGE>

                                                                           DRAFT

                              CANCERVAX CORPORATION
                SECOND AMENDED AND RESTATED 2000 STOCK INCENTIVE
                                      PLAN

                             STOCK OPTION AGREEMENT

         Pursuant to your Stock Option Grant Notice ("Grant Notice") and this
Stock Option Agreement, CancerVax Corporation has granted you an Option under
its Second Amended and Restated 2000 Stock Incentive Plan (the "Plan"), to
purchase the number of shares of the Company's Common Stock indicated in your
Grant Notice (the "Shares") at the exercise price indicated in your Grant
Notice. Capitalized terms not explicitly defined in this Stock Option Agreement
but defined in the Plan shall have the same definitions as in the Plan.

         The details of the Option are as follows:

         1.       VESTING AND EXERCISABILITY. Subject to the limitations
contained herein, the Option will vest and become exercisable as provided in
your Grant Notice, provided that vesting will cease upon the termination of your
employment or service relationship with the Company or a Related Corporation and
the unvested portion of the Option will terminate.

         2.       SECURITIES LAW COMPLIANCE. Notwithstanding any other provision
of this Agreement, you may not exercise the Option unless the Shares issuable
upon exercise are registered under the Securities Act or, if such Shares are not
then so registered, the Company has determined that such exercise and issuance
would be exempt from the registration requirements of the Securities Act. The
exercise of the Option must also comply with other applicable laws and
regulations governing the Option, and you may not exercise the Option if the
Company determines that such exercise would not be in material compliance with
such laws and regulations.

         3.       INCENTIVE STOCK OPTION QUALIFICATION. If so designated in your
Grant Notice, all or a portion of the Option is intended to qualify as an
Incentive Stock Option under federal income tax law, but the Company does not
represent or guarantee that the Option qualifies as such.

         If the Option has been designated as an Incentive Stock Option and the
aggregate Fair Market Value (determined as of the grant date) of the shares of
Common Stock subject to the portions of the Option and all other Incentive Stock
Options you hold that first become exercisable during any calendar year exceeds
$100,000, any excess portion will be treated as a Nonqualified Stock Option,
unless the Internal Revenue Service changes the rules and regulations governing
the $100,000 limit for Incentive Stock Options. A portion of the Option may be
treated as a Nonqualified Stock Option if certain events cause exercisability of
the Option to accelerate.

         4.       NOTICE OF DISQUALIFYING DISPOSITION. To the extent the Option
has been designated as an Incentive Stock Option, to obtain certain tax benefits
afforded to Incentive Stock Options you must hold the Shares issued upon the
exercise of the Option for two years

<PAGE>

after the Grant Date and one year after the date of exercise. You may be subject
to the alternative minimum tax at the time of exercise. You should obtain tax
advice when exercising the Option and prior to the disposition of the Shares. By
accepting the Option, you agree to promptly notify the Company if you dispose of
any of the Shares within one year from the date you exercise all or part of the
Option or within two years from the Grant Date.

         5.       METHOD OF EXERCISE. You may exercise the Option by giving
written notice to the Company, in form and substance satisfactory to the
Company, which will state your election to exercise the Option and the number of
Shares for which you are exercising the Option. The written notice must be
accompanied by full payment of the exercise price for the number of Shares you
are purchasing. Such payment must be paid in cash or by check (acceptable to the
Plan Administrator) or, unless the Plan Administrator in its sole discretion
determines otherwise, either at the time the Option is granted or at any time
before it is exercised, in any combination of:

                  (a)      cash;

                  (b)      check (acceptable to the Plan Administrator);

                  (c)      tendering (either actually or, if the Common Stock is
registered under Section 12(b) or 12(g) of the Exchange Act, by attestation)
shares of Common Stock already owned by the Participant for at least six months
(or any shorter period necessary to avoid a charge to the Company's earnings for
financial reporting purposes) that on the day prior to the exercise date have a
Fair Market Value equal to the aggregate exercise price of the shares being
purchased under the Option;

                  (d)      if the Common Stock is registered under Section 12(b)
or 12(g) of the Exchange Act, delivery of a properly executed exercise notice,
together with irrevocable instructions to a brokerage firm designated by the
Company to deliver promptly to the Company the aggregate amount of sale or loan
proceeds to pay the Option exercise price and any withholding tax obligations
that may arise in connection with the exercise, all in accordance with the
regulations of the Federal Reserve Board; or

                  (e)      such other consideration as the Plan Administrator
may permit.

         6.       REPURCHASE AND FIRST REFUSAL RIGHTS. So long as the Common
Stock is not registered under the Exchange Act, the Company may, in its sole
discretion at the time of exercise, require you to sign a stock purchase
agreement, stockholders agreement and/or voting agreement, in the form to be
provided, pursuant to which you will agree that the Shares acquired by you upon
exercise of the Option will be subject to the Company's rights of first refusal,
repurchase rights, other transfer restrictions, certain voting restrictions or
other restrictions. Upon request to the Company, you may review a current form
of any of these agreements, as applicable, prior to exercise of the Option.

                                       -2-

<PAGE>

         7.       MARKET STANDOFF. By exercising the Option you agree that the
Shares will be subject to the market standoff restrictions on transfer set forth
in the Plan.

         8.       TREATMENT UPON TERMINATION OF EMPLOYMENT OR SERVICE
RELATIONSHIP. The unvested portion of the Option will terminate automatically
and without further notice immediately upon termination of your employment or
service relationship with the Company or a Related Corporation for any reason
(the "Employment Termination Date"). You may exercise the vested portion of the
Option as follows:

                  (a)      General Rule. Subject to clauses (b) and (c) below,
you must exercise the vested portion of the Option on or before the earlier
of (i) three months after your Employment Termination Date and (ii) the Option
Expiration Date;

                  (b)      Retirement or Disability. If your employment or
service relationship terminates due to Retirement or Disability, you must
exercise the vested portion of the Option on or before the earlier of (i) one
year after your Employment Termination Date and (ii) the Option Expiration Date.

                  (c)      Death. If your employment or service relationship
terminates due to your death, the vested portion of the Option must be exercised
on or before the earlier of (i) one year after your Employment Termination Date
and (ii) the Option Expiration Date. If you die after your Employment
Termination Date but while the Option is still exercisable, the vested portion
of the Option may be exercised until the earlier of (x) one year after the date
of death and (y) the Option Expiration Date; and

                  (d)      Cause. The vested portion of the Option will
automatically expire at the time the Company first notifies you of the
termination of your employment or service relationship with the Company or a
Related Corporation for Cause, unless the Plan Administrator determines
otherwise. If your employment or service relationship is suspended pending an
investigation of whether you will be terminated for Cause, all your rights under
the Option likewise will be suspended during the period of investigation. If any
facts that would constitute termination for Cause are discovered after your
Employment Termination Date, any Option you then hold may be immediately
terminated by the Plan Administrator.

         An Option designated as an Incentive Stock Option shall cease to
qualify for favorable tax treatment as an Incentive Stock Option to the extent
it is exercised (a) more than three months after the Employment Termination Date
if termination was for reasons other than death or disability (as defined in
Section 22(e)(3) of the Code), (b) more than one year after the Employment
Termination Date if termination was by reason of disability (as defined in
Section 22(e)(3) of the Code), or (c) after the Participant has been on leave of
absence for more than 90 days, unless the Participant's reemployment rights are
guaranteed by statute or contract.

    IT IS YOUR RESPONSIBILITY TO BE AWARE OF THE DATE THE OPTION TERMINATES.

                                      -3-

<PAGE>

         9.       LIMITED TRANSFERABILITY. During your lifetime only you can
exercise the Option. The Option is not transferable except by will or by the
applicable laws of descent and distribution, except that Nonqualified Stock
Options may be transferred to the extent permitted by the Plan Administrator and
the Plan. The Plan provides for exercise of the Option by a designated
beneficiary or the personal representative of your estate.

         10.      WITHHOLDING TAXES. As a condition to the exercise of any
portion of an Option, you must make such arrangements as the Company may require
for the satisfaction of any federal, state, local or foreign withholding tax
obligations that may arise in connection with such exercise.

         11.      OPTION NOT AN EMPLOYMENT OR SERVICE CONTRACT. Nothing in the
Plan or any Award granted under the Plan will be deemed to constitute an
employment contract or confer or be deemed to confer any right for you to
continue in the employ of, or to continue any other relationship with, the
Company or any Related Corporation or limit in any way the right of the Company
or any Related Corporation to terminate your employment or other relationship at
any time, with or without Cause.

         12.      NO RIGHT TO DAMAGES. You will have no right to bring a claim
or to receive damages if you are required to exercise the vested portion of the
Option within three months (one year in the case of Retirement, Disability or
death) of the Employment Termination Date or if any portion of the Option is
cancelled or expires unexercised. The loss of existing or potential profit in
Awards will not constitute an element of damages in the event of termination of
employment or service relationship for any reason even if the termination is in
violation of an obligation of the Company or a Related Corporation to you.

         13.      BINDING EFFECT. This Agreement will inure to the benefit of
the successors and assigns of the Company and be binding upon you and your
heirs, executors, administrators, successors and assigns.

         THE FOLLOWING SECTION 14 APPLIES ONLY TO NON-US RESIDENTS

         14.      LIMITATION ON RIGHTS; NO RIGHT TO FUTURE GRANTS; EXTRAORDINARY
ITEM OF COMPENSATION. By entering into this Agreement and accepting the grant of
the Option evidenced hereby, you acknowledge: (a) that the Plan is discretionary
in nature and may be suspended or terminated by the Company at any time; (b)
that the grant of the Option is a one-time benefit which does not create any
contractual or other right to receive future grants of options, or benefits in
lieu of options; (c) that all determinations with respect to any such future
grants, including, but not limited to, the times when options will be granted,
the number of shares subject to each option, the option price, and the time or
times when each option will be exercisable, will be at the sole discretion of
the Company; (d) that your participation in the Plan is voluntary; (e) that the
value of the Option is an extraordinary item of compensation which is outside
the scope of your employment contract, if any; (f) that the Option is not part
of normal or expected compensation for purposes of calculating any severance,
resignation, redundancy, end of service payments, bonuses, long-service awards,

                                       -4-

<PAGE>

pension or retirement benefits or similar payments; (g) that the vesting of the
Option ceases upon termination of employment or service relationship with the
Company for any reason except as may otherwise be explicitly provided in the
Plan or this Agreement or otherwise permitted by the Plan Administrator; (h)
that the future value of the Shares underlying the Option is unknown and cannot
be predicted with certainty; and (i) that if the Shares underlying the Option do
not increase in value, the Option will have no value.

         15.      EMPLOYEE DATA PRIVACY. By entering this Agreement, you (a)
authorize the Company and your employer, if different, and any agent of the
Company administering the Plan or providing Plan recordkeeping services, to
disclose to the Company or any of its affiliates any information and data the
Company requests in order to facilitate the grant of the Option and the
administration of the Plan; (b) waive any data privacy rights you may have with
respect to such information; and (c) authorize the Company and its agents to
store and transmit such information in electronic form.

                                       -5-<PAGE>

                                                                   EXHIBIT 10.20

                              CONSULTING AGREEMENT

         This Consulting Agreement (this "Agreement") is effective as of
December 15, 2000 (the "Effective Date"), and is entered into by and between
CancerVax Corporation, a Delaware corporation (the "Company"), and Donald L.
Morton, MD, an individual ("Consultant").

         This Agreement supercedes and replaces that certain Consulting
Agreement, dated December 15, 2000, by and among the Company and the Consultant.

                                    RECITALS

         A. Consultant possesses special skills, knowledge and qualifications
beneficial to the business of the Company.

         B. Prior hereto, Consultant and his affiliated entities have
contributed certain technology to the Company in exchange for capital stock of
the Company.

         C. The parties hereto desire to enter into an agreement under which
Consultant will provide services to the Company.

         D. The parties intend that Consultant shall be an independent
contractor with and to the Company under this Agreement and not an employee of
the Company.

         E. Company acknowledges that Consultant is a full-time employee of the
John Wayne Cancer Institute ("JWCI") and Consultant and Company are bound by the
JWCI's Uniform Consulting Provisions which are attached hereto as Exhibit A (the
"Uniform Consulting Provisions") and incorporated herein by specific reference.

         F. The Prior Agreement provides that an amendment or modification must
be signed in writing by the party against whom the enforcement of any such
amendment or modification is sought.

                                    AGREEMENT

         NOW, THEREFORE, in consideration of the mutual agreements and covenants
contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto hereby agree as
follows:

         1. Engagement and Term. The Company hereby engages Consultant to
provide services, and Consultant accepts such engagement, upon the terms and
conditions set forth herein for a term commencing on the date hereof and
terminating on the fourth anniversary hereof unless such engagement is sooner
terminated as hereinafter provided.

         2. Duties. Consultant shall (a) provide consulting services for the
Company to pursue, develop, license and commercialize all aspects of the
Company's products and technology, (b) consult on all medical and technical
matters requested by the Company, (c) serve as the

<PAGE>

Chairman of the Company's Scientific Advisory Board, and (d) perform such other
duties pertaining to the Company's business as the Company may reasonably
request from time to time, including, without limitation, participating in
presentations of the Company's products and technology to potential strategic
partners, investors and other parties. Such services may include, from time to
time, written reports on particular matters the Company may reasonably request.

         3. Nature of Services. Consultant shall perform diligently and to the
best of Consultant's talents, skills and expertise, all of the services which
Consultant is required to perform under this Agreement and shall devote, or be
available to devote, such time to the performance of these duties as may be
necessary therefor, but not more than thirty three (33) business days during any
twelve month period without the prior written agreement of the parties, which
agreement will address additional compensation for Consultant and any additional
terms and will be consistent with Consultant's employment with JWCI and the
Uniform Consulting Provisions. Consultant shall not delegate the performance of
any such services to any other person, firm or corporation without the prior
written consent of the Company, which consent the Company may grant or withhold
in its sole and absolute discretion. Subject to the foregoing and the provisions
of Section 7, Consultant shall have the right to engage in any other gainful
activities, ventures and businesses. Consultant will provide the services at
times and places that are mutually convenient to Consultant and to the Company.
Consultant will make a reasonable effort to attend scheduled meetings of the
Company's Scientific Advisory Board.

         The Company shall have the right, at any time and from time to time, to
hire any other person, firm or entity to provide all or any portion of the
services which Consultant has agreed to provide to the Company hereunder.
Whether or not the Company has hired any such other person, firm or entity, the
Company may, by notice to Consultant, in its sole and absolute discretion and
from time to time, cause Consultant to cease providing any one or more services
hereunder and/or withdraw and/or change any request for services theretofore
made by the Company to Consultant.

         4. Compensation. For the term of this Agreement, the Company shall pay
to Consultant and Consultant shall accept as payment in full for all obligations
hereunder and services rendered by Consultant to the Company hereunder a
consulting fee (the "Consulting Fee") equal to One Hundred Fifty Thousand
Dollars ($150,000) per annum, payable monthly in arrears on the last day of each
calendar month. For the avoidance of doubt, Consultant shall be entitled to the
Consulting Fee if he is able to perform the obligations and services hereunder
even though the Company does not assign Consultant sufficient services to
perform during the term of this Agreement.

         5. Reimbursement of Expenses. The Company shall reimburse Consultant
for all out-of-pocket expenses authorized by the Chief Executive Officer of the
Company and incurred by Consultant in the performance of Consultant's duties
hereunder, provided Consultant provides the Company, in accordance with the
Company's policies, reasonable documentation or substantiation of such expenses.

                                      -2-
<PAGE>

         6. Confidential Information and Inventions.

                  (a) Consultant recognizes and acknowledges that during the
course of Consultant's engagement by the Company, Consultant shall have access
to Confidential Information. "Confidential Information" means all material or
information not publicly known outside the Company and received or learned by
Consultant in the course of providing services hereunder or in serving as a
director, officer, member of the Scientific Advisory Board, employee, agent or
consultant with the Company prior to or after the date of this Agreement,
including, without limitation, any such material or information which relates to
any of the Company's products, services, technologies or any phase of its
operations, business or financial affairs or which was created for the Company
by Consultant hereunder. Confidential Information includes, but is not limited
to, the following types of materials and information (whether or not reduced to
writing): biological or chemical samples or materials, trade secrets,
inventions, drawings, file data, documentation, diagrams, specifications,
know-how, processes, formulas, models, flow charts, software in various stages
of development, source codes, object codes, research and development procedures,
test results, trial results, marketing techniques and materials, marketing and
development plans, price lists, pricing policies, business plans, information
relating to customers and/or suppliers' identities, characteristics and
agreements, financial information and projections and employee files.
Confidential Information also includes any materials or information which the
Company obtains from another party and which the Company treats and/or has an
obligation to treat as confidential or designates as Confidential Information,
whether or not owned or developed by the Company. Confidential Information shall
not include any information which is or becomes (A) generally available to the
public other than as a result of disclosure by Consultant in violation of any
agreement with the Company or (B) generally known in the industry in which the
Company is or may become involved other than as a result of disclosure by
Consultant in violation of any agreement with the Company. (The term "Company,"
as used in this Section 6, means not only CancerVax Corporation, but also any
company, partnership or entity which, directly or indirectly, controls, is
controlled by or is under common control with CancerVax Corporation.)

                  (b) Both during the term hereof and at all times thereafter,
all Confidential Information which Consultant now possesses, obtains during or
after the term hereof, or creates in the course of providing services to the
Company prior to the end of the term hereof will be held confidential by
Consultant, and Consultant will not (nor will Consultant assist any other person
to do so), directly or indirectly, (i) reveal, report, publish or disclose such
Confidential Information to any person, firm, corporation, association or other
entity for any reason or purpose whatsoever (other than in the course of
carrying out Consultant's duties hereunder or as expressly authorized by the
Company) or (ii) use such Confidential Information except for the benefit of the
Company and in the course of Consultant's engagement by the Company; provided,
however that the foregoing will not apply to the extent Consultant is required
to disclose any Confidential Information by applicable law or legal process so
long as Consultant promptly notifies the Company of such pending disclosure and
consults with the Company prior to such disclosure concerning the advisability
of seeking a protective order or other means of preserving the confidentiality
of the Confidential Information. In addition, Consultant shall comply with (I)
any additional confidentiality, non-disclosure and non-use requirements

                                      -3-
<PAGE>

imposed upon the Company in connection with receiving Confidential Information
from third parties if Consultant is notified of such additional obligations and
(II) the confidentiality, non-disclosure, and non-use requirements imposed upon
JWCI, Consultant, and Cancer Diagnostic Labs, Inc. ("CDL") under the
Cross-License Agreement dated July 24, 1998, between JWCI and the Company (as
assignee) (the "JWCI Cross-License"), the Contribution of Technology and
Exchange Agreement dated as of the date hereof between Consultant and the
Company, and the Agreement dated July 31, 2000, between CDL and the Company,
with respect to the materials and information licensed or assigned to the
Company thereunder and, with respect to the JWCI Cross-License Agreement,
licensed to JWCI by the Company. The Company acknowledges that (A) Consultant,
in connection with his full-time employment with JWCI, is the named investigator
on certain government grants and may be an investigator on future grants and (B)
data and information resulting from such government grants must be disclosed to
the sponsoring government agency and regulatory agencies and may be published,
subject to the JWCI Cross-License Agreement.

                  (c) Any designs, concepts, techniques, inventions,
discoveries, devices, processes, materials (biological, chemical or otherwise),
drawings, works of authorship, methods and formulas, together with any
improvements thereon or thereto, derivative works therefrom and know-how related
thereto, whether or not patentable or protectable by copyright, whether or not
reduced to practice, and whether or not fixed in a tangible medium of
expression, that are, in whole or in part, conceived, made or reduced to
practice by Consultant (either solely or in conjunction with others) during the
rendering of the services to be performed hereunder ("Inventions") will belong
exclusively to the Company and will be deemed part of the Confidential
Information for purposes of this Agreement.

                           (i)      Without limiting the foregoing, any such
Inventions will be deemed to be "works made for hire" and the Company will be
deemed to be the owner thereof, provided that in the event and to the extent
such works are determined not to constitute "works made for hire" as a matter of
law, Consultant hereby irrevocably assigns and transfers to the Company all
right, title and interest in and to any such Inventions, including but not
limited to all related patents and copyrights and all applications therefor and
filings and notification with respect thereto.

                           (ii)     Consultant will attempt to keep and maintain
adequate and current written records (in the form of notes, sketches, drawings
or such other form(s) as may be specified by the Company) of all Inventions made
by Consultant during the term hereof or thereafter (the rights to which, in
whole or in part, belong to or have been assigned to the Company pursuant to the
provisions of this Section 6), which records will be available at all times to
the Company and will remain the sole property of the Company. In the event that
(A) any Invention is made, conceived of or reduced to practice by Consultant,
either solely or in conjunction with others, during the term hereof, or (B) any
Invention is made, conceived of or reduced to practice by Consultant after the
term hereof which belongs exclusively to the Company pursuant to the provisions
of this Section 6, Consultant will promptly give notice and fully disclose in
writing such Invention to the Chief Executive Officer.

                                      -4-
<PAGE>

                           (iii)    Consultant will assist the Company, during
and subsequent to the term of this Agreement, to obtain, defend, maintain and
enforce for the Company's benefit, patents and copyrights in any country for any
and all Inventions, in whole or in part, the rights to which belong to or have
been assigned to the Company pursuant to the provisions of this Section 6.
Consultant will be paid at a reasonable consulting rate (e.g., $3,500 per day or
$425 per hour) for such assistance if it is rendered after the term of this
Agreement or, during the term of this Agreement, to the extent such assistance,
when added to the other services to be performed by Consultant for the Company
hereunder exceeds the amount of days of service Consultant may be requested to
provide pursuant to Section 3. Consultant agrees to execute all applications,
assignments, instruments and papers and perform all acts as the Company or its
counsel may reasonably deem necessary or desirable to obtain any patents or
copyrights in such Inventions and otherwise to defend, maintain or enforce the
interests of the Company therein. The Company understands the significant
demands on Consultant's time due to other responsibilities and will endeavor to
keep its requirements under this Section 6(c)(iii) to a minimum. In the event
the Company is unable to secure Consultant's signature on any document necessary
to apply for, prosecute, obtain, defend, maintain or enforce any patent,
copyright, or other right or protection relating to any such Invention, whether
due to mental or physical incapacity or any other cause, Consultant hereby
irrevocably designates and appoints the Company and each of its duly authorized
officers and agents as Consultant's agents and attorney-in-fact, to act for and
in Consultant's behalf and stead to execute and file any such document and to do
all other lawfully permitted acts to further the prosecution, issuance,
maintenance, defense, and enforcement of patents, copyrights, or other right or
protections with the same force and effect as if executed and delivered by
Consultant.

                  (d) All memoranda, notes, lists, records and other documents
(and all copies thereof) constituting Confidential Information (including
information relating to all Inventions which belong exclusively to the Company
pursuant to the provisions of this Section 6) made or compiled by Consultant or
made available to Consultant during or after the term hereof shall be the
Company's property, shall be kept confidential in accordance with the provisions
of this Section 6 and shall be delivered to the Company at any time on request
and in any event upon the termination of Consultant's engagement by the Company
for any reason.

         7. Noncompetition. Except as otherwise agreed between the parties in
writing and for so long as Consultant is obligated to provide consulting
services for the Company hereunder, Consultant shall not (a) engage or own any
interest in any for-profit activities, ventures or businesses ("Business") which
directly or indirectly conflict or compete with, or are substantially similar
to, the Company's field of business, which is and shall deemed to be the use of
immunotherapy or immunomodulation through the use of vaccines, antibodies,
peptides, nucleotides or any other biological materials to treat or prevent
cancer (the "Field"), or (b) commit any other act or assist others to commit any
other act with the intent to, or which could be expected to, injure the business
of the Company. Notwithstanding the foregoing, Consultant may (i) own up to 5%
of the outstanding stock of any publicly traded company or mutual fund or
outstanding stock of any private company if the stock was acquired by Consultant
as an investor in a venture capital financing, (ii) engage in the practice of
medicine, (iii) in his capacity as a physician, treat patients and (iv) serve as
a principal investigator at a non-profit

                                      -5-
<PAGE>

research institution or academic institution, including JWCI, for a clinical
trial in the Field if Consultant and the institution disclose basic information
about the proposed clinical trial (e.g. identity of Business, type of product,
and the particular patient population to be included in the clinical trial) in
advance to the Company and if, with respect to a clinical trial that is to be
funded by a Business with rights to resulting technology or information or that
is for a product, process or method being developed, sold or controlled by a
Business, the Company has given its consent to such service as a principal
investigator for such clinical trial, which consent shall not be unreasonably
withheld or delayed. Otherwise, Consultant shall not serve as a principal
investigator for such a clinical trial in the Field which could lead to a
commercial product, process or method. If Consultant or the institution dispute
the reasonableness of the Company withholding such consent, the question of
reasonableness shall be settled by arbitration in accordance with Section 19.

                  The parties understand and recognize that (I) Consultant is a
world-recognized cancer surgeon who is employed by and affiliated with JWCI,
(II) Consultant has an interest (fiduciary or otherwise) in the Company and its
success in its business endeavors as a founder, major stockholder, director,
chairman of the Scientific Advisory Board, and consultant to the Company and
currently has, and will have in the future, access to the Company's confidential
information, technology and business plans, (III) Consultant and his affiliated,
for-profit entities are assignors or transferors to the Company of the current
core assets and technologies of the Company and are subject to certain
obligations in connection therewith, and (IV) the Company does not want to
inhibit Consultant's practice of medicine or to unreasonably inhibit his service
to the non-profit research and development activities of JWCI or other
non-profit research institutions or academic institutions with which Consultant
may become affiliated.

         8. Solicitation of Employees. For so long as Consultant is obligated to
provide consulting services for the Company hereunder and for an additional
period of one year thereafter (collectively, the "Restricted Period"),
Consultant shall not directly or indirectly solicit or encourage any employee of
the Company to leave the employ of the Company.

         9. Solicitation of Consultants. Consultant shall not, during the
Restricted Period, directly or indirectly, solicit or encourage (a) any
consultant to the Company to cease or reduce the consultant's services or
relationship with the Company or (b) any former consultant to the Company not to
provide future services to the Company.

         10. Solicitation of Suppliers/Customers. Consultant shall not, during
the Restricted Period, directly or indirectly, solicit or encourage any
strategic partners, customers, suppliers or vendors to terminate or reduce their
relationship with the Company or not to enter into any business or relationship
with the Company.

         11. Use of Company Name. Consultant shall not make any written use of
or reference to the Company's name for any marketing, public relations,
advertising, display or other business purpose or make any use of the Company's
facilities for any activity unrelated to the express business purposes and
interests of the Company under this Agreement without the prior written consent
of the Company, which consent may be granted or withheld in the Company's sole
and absolute discretion.

                                      -6-
<PAGE>

         12. Restrictive Covenants; Survival. Consultant agrees that the
obligations, covenants and agreements of Consultant and the rights of the
Company set forth in Sections 6, 7, 8, 9, 10, 11 and 17 (the "Restrictive
Covenants") shall survive any termination or expiration of this Agreement. In
addition, any accrued obligations and the provisions of Sections 13, 14, 15, 19,
20, 21, 22, 23 (last sentence), 29 and 30 shall survive any termination or
expiration of this Agreement.

         13. Rights and Remedies Upon Breach. If Consultant breaches or
threatens to commit a breach of any of the provisions of the Restrictive
Covenants, the Company shall have the right and remedy to have the Restrictive
Covenants specifically enforced by any court having equity jurisdiction, all
without the need to post a bond or any other security or to prove any amount of
actual damage, such right and remedy shall be in addition to, and not in lieu
of, any other rights and remedies available to the Company under law or in
equity, and it being acknowledged and agreed that any such breach or threatened
breach will cause irreparable injury to the Company and that money damages will
not provide adequate remedy to the Company.

         14. Severability of Covenants/Blue Pencilling. If any court determines
that any of the Restrictive Covenants, or any part thereof, is invalid or
unenforceable, the remainder of the Restrictive Covenants shall not thereby be
affected and shall be given full effect, without regard to the invalid portions.

         15. Enforceability in Jurisdictions. The Company and Consultant intend
to and do hereby confer jurisdiction to enforce the Restrictive Covenants upon
the courts of any jurisdiction within the geographical scope of such covenants.
If the courts of any one or more of such jurisdictions hold the Restrictive
Covenants wholly unenforceable by reason of the breadth of such scope or
otherwise, it is the intention of the Company and Consultant that such
determination not bar or in any way affect the right of the Company to the
relief provided above in the courts of any other jurisdiction within the
geographical scope of such covenants, as to breaches of such covenants in such
other respective jurisdictions, such covenants as they relate to each
jurisdiction being, for this purpose, severable into diverse and independent
covenants.

         16. Termination. In addition to any other termination provisions
contained herein, this Agreement shall be terminated:

                  (a) at the election of Consultant for Good Reason, or the
Company for Cause;

                  (b) upon the death or Permanent Disability of Consultant; or

                  (c) sixty (60) days after the Company has given written notice
to Consultant that the Company's Board of Directors has determined by unanimous
vote (with Consultant abstaining) that this Agreement shall be terminated
without Cause; provided however, that Consultant shall be entitled to continue
to receive the payments set forth in Section 4 through the end of the normal
term of this Agreement if this Agreement is terminated pursuant to this Section
16 (c).

                                      -7-
<PAGE>

         Upon termination of this Agreement, Consultant shall not be obligated
to render any additional services to the Company and, subject to Section 16(c)
above, the Company shall not be obligated to make any additional payments to
Consultant, whether in the form of Consulting Fees or otherwise; provided,
however, that the Company shall pay Consultant for any uncompensated services
heretofore rendered by Consultant and, in accordance with Section 5, for any
unreimbursed out-of-pocket expenses incurred prior to termination.

                  For purposes of this Section 16, "Cause" shall mean any
material breach by Consultant of his obligations to the Company under this
Agreement and the failure of Consultant to cure such breach within fifteen (15)
days after receipt of written notice from the Company.

                  For purposes of this Section 16, "Good Reason" shall mean:

                  (i)      any material breach by the Company of its obligations
to Consultant under this Agreement and the failure of the Company to cure such
breach within fifteen (15) days after receipt of written notice from Consultant;
or

                  (ii)     there has been a Change of Control of the Company and
Consultant has given written notice to the Company within ninety (90) days after
such Change of Control that Consultant is electing to terminate this Agreement,
which termination shall be effective sixty (60) days from the date such notice
is given unless the Company requests in writing an earlier termination date.

                  For purposes of this Section 16, "Permanent Disability" shall
mean a determination of Permanent Disability under the Stockholders' Agreement
dated as of the date hereof among the Company, Consultant, OncoVac, Inc.,
investors in the Company and JWCI.

                  For purposes of this Section 16, "Change of Control" means
consummation of either (a) a merger or consolidation of the Company with or into
any other entity or person, or (b) a sale, lease, exchange, or other transfer in
one transaction or series of related transactions of all or substantially all of
the Company's outstanding securities or all or substantially all of the
Company's assets; provided, however, that a Change of Control shall not include
a Related Party Transaction. "Related Party Transaction" means (i) a merger or
consolidation of the Company in which the holders of the voting securities of
the Company immediately prior to the merger or consolidation hold at least a
majority of the voting securities in the Successor Entity immediately after the
merger or consolidation, (ii) a sale, lease, exchange, or other transaction in
one transaction or a series of related transactions, of all or substantially all
of the Company's assets to a wholly owned subsidiary entity, (iii) a
reincorporation of the Company, or (iv) a transaction undertaken for the sole
purpose of creating a holding company that will be owned in substantially the
same proportion by the persons who held the Company's securities immediately
before such transaction. "Successor Entity" means the surviving entity, the
successor entity, or its parent entity, as applicable.

         17. Return of the Company's Property. If this Agreement is terminated
for any of the foregoing reasons, the Company shall have the right, at its
option, to require Consultant to vacate Consultant's offices, if any, on the
Company's premises prior to the effective date of termination

                                      -8-
<PAGE>

and to cease all activities on the Company's behalf. Upon the termination or
expiration of this Agreement, Consultant shall immediately surrender to the
Company all notes, data, sketches, drawings, manuals, documents, records,
databases, programs, computer diskettes, printouts, blueprints, memoranda,
specifications, customer lists, financial reports, equipment and all other
physical forms of expression incorporating or containing any Confidential
Information, and all lists, books and records of, or in connection with, the
Company's business, and all other property belonging to the Company, it being
distinctly understood that all such items are the property of the Company.

         18. No Conflicting Agreements. Consultant represents and warrants to
the Company that, except as provided below, there are no agreements, commitments
or relationships to which Consultant is a party which would prevent Consultant's
timely and complete performance of the terms and conditions of this Agreement,
and Consultant shall not enter into any such agreement, commitment or
relationship during the term of this Agreement. Notwithstanding anything in this
Agreement to the contrary, the Company acknowledges that since 1991 Consultant
has been an employee and officer of JWCI, a nonprofit public benefit corporation
engaged in various aspects of oncology research, development and education, and
although Consultant is not currently functioning as either an officer or a
member of the board of directors of JWCI, Consultant is expected to return to
such duties in the future. Consultant has disclosed to the Company the relevant
terms and conditions of his employment with JWCI, including those terms and
conditions which relate to conflicts of interest and ownership and assignment of
intellectual property rights. As required under the terms of his written
agreements with JWCI, Consultant has also disclosed to JWCI his indirect equity
interest in and consulting relationship with the Company and has received JWCI's
written acknowledgement thereof in the form attached hereto as Exhibit B.

         19. Arbitration. Except for action by the Company pursuant to Sections
13 and 15 or any injunctive relief sought by a party, any dispute or controversy
arising under this Agreement or concerning Consultant's engagement by the
Company (including, without limitation, any controversy as to the arbitrability
of any dispute) shall be settled exclusively by arbitration to be held in Los
Angeles, California, before a single arbitrator in accordance with the
Commercial Arbitration Rules of the American Arbitration Association then in
effect, provided the dispute or controversy has first been identified in writing
from one party to the other party, together with a proposed resolution of the
dispute or controversy, and the parties have, after good faith efforts, not
resolved the dispute or controversy within twenty (20) days of such notice or
not agreed to extend the time period in which to seek good faith resolution.
Discovery shall be permitted to the same extent as in a proceeding under the
Federal Rules of Civil Procedure, including (without limitation) such discovery
as is specifically authorized by section 1283.05 of the California Code of Civil
Procedure, without need of prior leave of the arbitrator under section
1283.05(e) of such Code. The arbitrator shall issue a written arbitration award
that sets forth the essential findings and conclusions on which the award is
based and such award shall be subject to judicial review sufficient to ensure
that the arbitrator complies with applicable law. Judgment may be entered on the
arbitrator's award in any court having jurisdiction, and the parties consent to
the jurisdiction of the Los Angeles courts for that purpose. All fees and
expenses of the arbitrator and such Association shall be paid by the Company.

                                      -9-
<PAGE>

         20. Indemnification. Company shall indemnify, defend and hold harmless
the Consultant, to the full extent permitted by law, from and against any and
all claims, demands, liabilities, losses, expenses, costs, obligations,
recoveries or damages of any nature whatsoever, initiated by third parties,
whether accrued, absolute, contingent or otherwise, including without limitation
court costs and attorneys' fees (whether or not suit is filed), arising by
reason of the fact that Consultant is or was a consultant of the Company, where
the basis of any such claim or demand is alleged action by Consultant in an
official capacity as such consultant of the Company; provided, however, that the
Company shall not indemnify, defend or hold harmless the Consultant for any
willful tortious conduct of the Consultant.

         21. Notices. All notices, requests and other communications of any kind
which either party hereto may be required or desires to serve upon the other
party under the terms of this Agreement shall be in writing and shall be
delivered by courier or other means of personal service (including by means of a
nationally recognized courier service or a professional messenger service), or
sent by telecopy or mailed first class, postage prepaid by certified mail,
return receipt requested, in all cases addressed to:

                  If to Consultant:     Dr. Donald Morton
                                        1374 Bella Oceana Vista
                                        Pacific Palisades, CA 90630
                                        Fax No. (310) 582-7185

                  If to the Company:    CancerVax Corporation
                                        P. O. Box 5620 Paseo Del Norte #127-541
                                        Carlsbad, CA 92008
                                        Fax No. (858) 756-3567
                                        Attention: Chief Executive Officer

All notices, requests and other communications shall be deemed given on the date
of actual receipt or delivery to the address set forth above. In case of service
by telecopy, a copy of such notice shall be personally delivered or sent by
registered or certified mail, in the manner set forth above, within three (3)
business days thereafter. Either party hereto may from time to time by notice in
writing served as set forth above designate a different address or a different
or additional person to which all such notices or communications thereafter are
to be given.

         22. Attorneys' Fees. In the event of any action, proceeding or
arbitration between the parties hereto to enforce any provision or right
hereunder, the unsuccessful party to such action or proceeding shall pay the
successful party all costs and expenses, including but not limited to, actual
attorneys' fees incurred therein by such successful party, which cost, expenses
and attorneys' fees shall be included in and as a part of any judgment or award
rendered in such action or proceeding.

         23. Relationship and Authority. The relationship between the Company
and Consultant intended to be created by this Agreement is that of client and
independent contractor, and nothing herein contained shall be construed as
creating a relationship of employer and employee or principal and agent between
them. Consultant shall neither act nor make any representation

                                      -10-
<PAGE>

that Consultant is authorized to act as an employee, agent or officer of the
Company. Consultant shall have no authority to bind the Company in his capacity
as a consultant to the Company. The Company will not make deductions for taxes
from any amounts payable to Consultant hereunder. Consultant shall be
responsible for and shall pay all taxes related to the receipt of payments
hereunder. In the event the Internal Revenue Service or other taxing authority
shall seek to collect withholding taxes (or penalties or interest related
thereto) from the Company, Consultant shall give reasonable proof and supporting
documents, if reasonably requested, to verify the payment by Consultant of
amounts related to such taxes.

         24. Assignment. The services to be rendered and the duties to be
performed by Consultant hereunder are of a unique and personal nature. Nothing
contained in this Agreement shall be construed to permit the assignment by
Consultant of any right or obligation under this Agreement and any such
assignment is expressly prohibited without the prior written consent of the
Company, which may be granted or withheld in the Company's sole and absolute
discretion. The Company shall have the right to assign its rights and
obligations under this Agreement in connection with a merger, consolidation or
reorganization of the Company or to a purchaser or transferee of all or
substantially all of its assets that relate to the Field.

         25. Section Headings. The headings of the several paragraphs of this
Agreement are inserted solely for convenience of reference and are not a part
hereof and are not intended to govern, limit or aid in the construction of any
term or provision hereof.

         26. Entire Agreement. This Agreement (including any exhibits hereto)
and the agreements, documents and instruments to be executed and delivered
pursuant hereto or thereto are intended to embody the final, complete and
exclusive agreement among the parties with respect to the subject matter hereof,
are intended to supersede all prior and contemporaneous agreements,
understandings and representations written or oral, with respect thereto, and
may not be contradicted by evidence of any such prior or contemporaneous
agreement, understanding or representation, whether written or oral.

         27. Engagement at Will. Any continuance of Consultant's engagement by
the Company and Consultant after the expiration of the term of this Agreement
shall be deemed an engagement at will and shall be subject to termination with
or without cause by either Company or Consultant upon delivery of notice thereof
to the other party. In all other respects, any such continuance of engagement
shall be upon the terms and conditions as set forth herein or as otherwise
mutually agreed upon by the parties hereto.

         28. Waiver; Modification. No provision of this Agreement may be
amended, modified or waived except by an agreement in writing signed by the
party against whom the enforcement of any such waiver, amendment or modification
is sought.

         29. Severability. The provisions of this Agreement are severable, and
in the event that any provision is declared invalid, this Agreement shall be
interpreted as if such invalid provision were not contained herein.

                                      -11-
<PAGE>

         30. Applicable Law and Venue. This Agreement shall constitute a
contract under the laws of the State of California and shall be governed and
construed in accordance with the laws of said State and without regard to the
conflicts of laws principles thereof. Subject to the provisions of Section 19,
and except as provided in Section 15, any action or proceeding brought hereunder
shall be brought in the state or federal courts sitting in Los Angeles,
California, the parties hereto hereby waiving any claim or defense that such
forum in not convenient or proper. Each party hereby agrees that any such court
shall have in personam jurisdiction over it, consents to service of process in
any manner authorized by California law, and agrees that a final judgment in any
such action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner specified by law.

         31. Further Assurances. The Company and Consultant shall, whenever and
as often as reasonably requested to do so by the other party, execute,
acknowledge and deliver or cause to be executed, acknowledged or delivered, any
and all agreements and instruments as may be necessary, expedient or proper in
the opinion of the requesting party to carry out the intent and purposes of this
Agreement.

         32. Gender; Tense; etc. Where the context or construction herein
requires, all words applied in the plural shall be deemed to include the
singular, and vice versa; the masculine shall include the feminine and neuter,
and vice versa; and the present tense shall include the past and future tenses,
and vice versa.

         33. Counterparts. This Agreement may be executed simultaneously in any
number of counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same agreement.

         34. Amendment and Restatement of Prior Agreement. As of the Effective
Date, this Agreement hereby amends, restates and completely supersedes the Prior
Agreement and, except as otherwise set forth herein, such agreement shall be
terminated, void and of no further effect as of the Effective Date.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                      -12-
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement,
effective as of the day and year first set forth above.

                                      CancerVax Corporation,
                                      a Delaware corporation

                                      By: /s/ David F. Hale
                                          --------------------------------------
                                      Name:  David F. Hale
                                      Title: Chief Executive Officer

                                           /s/ Donald L. Mortn
                                      ------------------------------------------
                                      Dr. Donald L. Morton

                    [SIGNATURE PAGE TO CONSULTING AGREEMENT]

<PAGE>

                                    EXHIBIT A

                         THE JOHN WAYNE CANCER INSTITUTE
                          UNIFORM CONSULTING PROVISIONS

1.       All arrangements and agreements in which a member of the staff of the
         John Wayne Cancer Institute (hereinafter "JWCI") provides consulting
         services to any profit making or commercial organization (hereinafter
         the "Company") shall refer to these Uniform Consulting Agreement
         Provisions by specific reference and attaching same to the agreement or
         include same verbatim in the agreement. No such agreement shall be of
         any force or effect unless it is subject to these provisions and is
         approved in writing by the Director of Technology Transfer of the John
         Wayne Cancer Institute.

2.       JWCI staff members shall spend no more that a total of twenty percent
         of their professional effort in consulting services for all Companies.
         Consulting agreements shall specify the amount of time to be expended
         in consulting for the Company. Consulting fees shall be paid directly
         to the consultant. Such consulting services shall not involve any
         research or laboratory work at the facilities of JWCI.

3.       Neither the name nor reputation of JWCI or the John Wayne name or image
         shall be publicized or exploited directly or indirectly by the Company.
         The Company and the consultant shall hold JWCI and their officers,
         directors and employees harmless from all claims, charges, damages and
         judgments arising from consulting services and shall indemnify JWCI for
         costs, direct or indirect, of defending any action arising from the
         consulting agreement or services performed thereunder. Neither the
         Company nor the consultant shall use any services, personnel,
         facilities or equipment of JWCI in performing consulting services.

4.       Consultant's rights, title and interest in inventions, discoveries and
         developments arising from Company funded consulting services made
         solely or jointly with Company employees or agents may be assigned to
         the Company, so long as the provisions in section 5 below are not
         applicable.

5.       The Company shall not obtain any rights in or respecting any invention,
         discovery or development of the consultant which: (i) had been (a)
         conceived, (b) reduced to practice, (c) published, or (d) submitted for
         publication, by the consultant before the effective date of the
         consulting agreement; or (ii) had been at any time conceived or reduced
         to practice independent of consulting services performed hereafter; or
         (iii) relates to work conducted within JWCI (but not to work for the
         Company outside of JWCI).

6.       The Company shall have no rights or interests in any of the inventions,
         discoveries, developments, improvements or products which may arise
         from the research or other scientific work performed by the consultant
         outside the scope of the consulting agreement or performed by other
         scientists of JWCI, except as provided in agreements between the
         Company and JWCI. Further, it is understood that the consultant shall
         not disclose to the Company any such research or other scientific work
         to the extent that any such disclosure might impair the patent rights
         or the proprietary rights of JWCI or other third parties, except as
         provided in agreements between the Company and either JWCI or the other
         third parties.

<PAGE>

7.       Determination of inventorship, conception, and reduction to practice
         shall be determined by counsel for JWCI and counsel for the Company
         according to the patent laws of the United States.

8.       Except for information governed by any agreements between or among
         JWCI, the Company and/or the consultant, nothing in the consulting
         agreement shall limit or be construed to limit the right of consultant
         or JWCI to use or publish information which (a) was in the public
         domain before the consulting services were performed, (b) was known to
         consultant or JWCI, respectively, before the consulting services were
         performed, (c) was developed or acquired independently of the Company
         or JWCI, or (d) becomes public knowledge without breach by consultant
         of any obligations of confidence to Company or JWCI.

9.       Upon termination of consulting services, the consultant shall, if
         requested by the Company, leave all notes and records of his/her
         consulting services with the Company, but shall be entitled to retain
         one copy thereof for archival purposes, subject to any obligations of
         confidence to the Company.

10.      If under the consulting agreement the Company calls upon the consultant
         to testify in any expert capacity, in Court, depositions or otherwise,
         the Company shall pay consultant a reasonable and customary fee for all
         time spent in preparing for and giving such testimony.

11.      The consulting agreement and these provisions shall be construed and
         enforced in accordance with the laws of the State of California and the
         United States patent laws.

         Effective as of December 15, 2000.

                  ACCEPTED:

                  Company

                                    By: /s/ David F. Hale
                                        ----------------------------------------
                                    Name:  David F. Hale
                                    Title: President and CEO

         Consultant

                                       /s/ Donald L. Morton
                                       -----------------------------------------
                                    Donald L. Morton, M.D.

                  The John Wayne Cancer Institute

                                    By:_________________________________________
                                    Name:_______________________________________
                                    Title:______________________________________

                                    By:_________________________________________
                                    Name:_______________________________________
                                    Title:______________________________________

<PAGE>

                                    EXHIBIT B

                                 ACKNOWLEDGMENT

         In accordance with that certain Consulting Agreement by and between
Donald L. Morton, M.D. ("Consultant") and CancerVax Corporation, a Delaware
corporation (the "Company"), of even date herewith (the "Agreement"), and
notwithstanding anything to the contrary in that certain Employee
Confidentiality and Intellectual Property Policy Agreement by and between John
Wayne Cancer Institute ("JWCI") and Consultant dated November 22, 1999 (the
"I.P. Agreement") and that certain Employment Agreement by and between JWCI and
Consultant undated (the "Employment Agreement"), JWCI, as a stockholder of the
Company and in order to induce the Company to enter into the Agreement with
Consultant, hereby acknowledges and agree that Consultant shall be permitted to
perform the duties and comply with the terms of the Agreement. JWCI further
acknowledges and agrees hereby that (a) Consultant's rights, title and interest
in Inventions (as defined in the Agreement) which result from consulting
services performed for the Company under the Agreement have been assigned to the
Company in accordance with Section 4 of the Uniform Consulting Provisions
attached as Exhibit A to the Agreement and (b) the disclosure and handling of
approval of clinical trials in the Field (as defined in Section 7 of the
Agreement) where Consultant is the principal investigator will be in accordance
with Section 7 of the Agreement.

         Effective as of December 15, 2000.

CANCERVAX CORPORATION                          JOHN WAYNE CANCER INSTITUTE

By:_______________________________             By:______________________________
Name: David F. Hale                            Name:____________________________
Title: President & Chief Executive Officer     Title:___________________________

                                               By:  ____________________________
                                               Name:____________________________
                                               Title:___________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]